Moomoo AI 已提取核心信息
Heart Test Laboratories, Inc., a company listed on The Nasdaq Stock Market under the trading symbol HSCS, successfully held a reconvened Annual Meeting on February 15, 2024. The purpose of the meeting was to vote on Proposal 7, which aimed to amend the company's Certificate of Formation to decrease the number of shares required to establish a quorum for shareholder meetings. This proposal was previously presented at the Annual Meeting on January 17, 2024, but did not receive sufficient votes to pass. Following additional solicitation of votes, shareholders approved the amendment with 27,172,440 votes for, 1,298,890 against, 362,117 abstentions, and 1,015,919 broker non-votes. The details of the proposal were outlined in the definitive proxy statement filed with the SEC on December 8, 2023. Heart Test Laboratories is identified as an emerging growth company and has its principal executive offices in Southlake, Texas.
Heart Test Laboratories, Inc., a company listed on The Nasdaq Stock Market under the trading symbol HSCS, successfully held a reconvened Annual Meeting on February 15, 2024. The purpose of the meeting was to vote on Proposal 7, which aimed to amend the company's Certificate of Formation to decrease the number of shares required to establish a quorum for shareholder meetings. This proposal was previously presented at the Annual Meeting on January 17, 2024, but did not receive sufficient votes to pass. Following additional solicitation of votes, shareholders approved the amendment with 27,172,440 votes for, 1,298,890 against, 362,117 abstentions, and 1,015,919 broker non-votes. The details of the proposal were outlined in the definitive proxy statement filed with the SEC on December 8, 2023. Heart Test Laboratories is identified as an emerging growth company and has its principal executive offices in Southlake, Texas.
Heart Test Laboratories, Inc. 是一家在纳斯达克股票市场上市的公司，交易代码为HSCS，该公司于2024年2月15日成功举行了续会的年会。会议的目的是对第7号提案进行表决，该提案旨在修改公司的成立证书，以减少确定股东大会法定人数所需的股票数量。该提案此前曾在2024年1月17日的年会上提出，但没有获得足够的选票通过。在进一步征集投票后，股东们以27,172,440票赞成、1,298,890票反对、362,117票弃权和1,015,919张经纪人无票批准了该修正案。该提案的细节已在2023年12月8日向美国证券交易委员会提交的最终委托书中概述。心脏测试实验室被确定为一家新兴的成长型公司，其主要执行办公室位于德克萨斯州的绍斯莱克。
Heart Test Laboratories, Inc. 是一家在纳斯达克股票市场上市的公司，交易代码为HSCS，该公司于2024年2月15日成功举行了续会的年会。会议的目的是对第7号提案进行表决，该提案旨在修改公司的成立证书，以减少确定股东大会法定人数所需的股票数量。该提案此前曾在2024年1月17日的年会上提出，但没有获得足够的选票通过。在进一步征集投票后，股东们以27,172,440票赞成、1,298,890票反对、362,117票弃权和1,015,919张经纪人无票批准了该修正案。该提案的细节已在2023年12月8日向美国证券交易委员会提交的最终委托书中概述。心脏测试实验室被确定为一家新兴的成长型公司，其主要执行办公室位于德克萨斯州的绍斯莱克。
有用
没用
